Cargando…

Recombinant Factor VIIa Reduces Bleeding after Blunt Liver Injury in a Pig Model of Dilutional Coagulopathy under Severe Hypothermia

BACKGROUND: Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and other rare bleeding disorders, but has also been used in various other clinical conditions to terminate life-threatening bleeding. Underlying conditions (e.g. coagulopathy) and dosing may affect tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spronk, Henri M. H., Braunschweig, Till, Rossaint, Rolf, Wüst, Dirk C., van Oerle, Rene, Lauritzen, Brian, Tolba, Rene, Grottke, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476676/ https://www.ncbi.nlm.nih.gov/pubmed/26098426 http://dx.doi.org/10.1371/journal.pone.0113979

Ejemplares similares

Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury
por: Grottke, Oliver, et al.
Publicado: (2010)

Thrombin Generation Capacity of Prothrombin Complex Concentrate in an In Vitro Dilutional Model
por: Grottke, Oliver, et al.
Publicado: (2013)

Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven(®))
por: Viuff, D., et al.
Publicado: (2008)

Acquired bleeding model induced by dilutional coagulopathy in the rabbit
por: Pragst, I, et al.
Publicado: (2009)

Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
por: Grottke, Oliver, et al.
Publicado: (2014)

Use of a specific antidote to dabigatran (idarucizumab) reduces blood loss and mortality in dabigatran-induced and trauma-induced bleeding in pigs
por: Honickel, M, et al.
Publicado: (2014)

Factor VIIa for severe cardiac surgical bleeding
por: Diprose, P, et al.
Publicado: (2002)

Fibrinogen in dilutional coagulopathy: a dose study in pigs
por: Martini, J, et al.
Publicado: (2010)

The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition
por: Rossaint, Rolf, et al.
Publicado: (2023)

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
por: Meeks, Shannon L., et al.
Publicado: (2019)

Recombinant Factor VIIa Use for Endoscopic Retrograde Cholangiopancreatography With Sphincterotomy in a Patient With Choledocholithiasis and Unusual Coagulopathy
por: Abdulsamad, Molham, et al.
Publicado: (2017)

Global Characterisation of Coagulopathy in Isolated Traumatic Brain Injury (iTBI): A CENTER-TBI Analysis
por: Böhm, Julia K., et al.
Publicado: (2020)

The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition
por: Spahn, Donat R., et al.
Publicado: (2019)

Management of bleeding and coagulopathy following major trauma: an updated European guideline
por: Spahn, Donat R, et al.
Publicado: (2013)

Prothrombin complex concentrate restores haemostasis in a dabigatran anticoagulated polytrauma pig model
por: Honickel, M, et al.
Publicado: (2014)

Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
por: Puetz, John
Publicado: (2010)

An in vitro evaluation of standard rotational thromboelastography in monitoring of effects of recombinant factor VIIa on coagulopathy induced by hydroxy ethyl starch
por: Engström, Martin, et al.
Publicado: (2005)

The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
por: Rossaint, Rolf, et al.
Publicado: (2016)

Effects of Fibrinogen Concentrate on Thrombin Generation, Thromboelastometry Parameters, and Laboratory Coagulation Testing in a 24-Hour Porcine Trauma Model
por: Zentai, Christian, et al.
Publicado: (2015)

Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution
por: Grottke, Oliver, et al.
Publicado: (2019)

Violin concertos in C major, Hob. VIIa:1 ; in G major, Hob. VIIa:4 ; in A major, Hob. VIIa:3 /
por: Haydn, Joseph, 1732-1809
Publicado: (1989)

Management of Coagulopathy in Bleeding Patients
por: Hofer, Stefan, et al.
Publicado: (2021)

Efficacy of idarucizumab, prothrombin complex concentrate (PCC) and activated PCC to reverse the anticoagulatory potential of dabigatran in a porcine polytrauma model
por: Honickel, M, et al.
Publicado: (2015)

The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework
por: Lin, Y, et al.
Publicado: (2012)

Recombinant factor VIIa for variceal bleeding in liver cirrhosis: still only a hope
por: Qi, Xingshun, et al.
Publicado: (2017)

COVID-19 coagulopathy, thrombosis, and bleeding
por: Chan, Noel C., et al.
Publicado: (2020)

Role of Factor VII in Correcting Dilutional Coagulopathy and Reducing Re-operations for Bleeding Following Non-traumatic Major Gastrointestinal and Abdominal Surgery
por: Tsai, Thomas C., et al.
Publicado: (2010)

Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials
por: Rizoli, Sandro B, et al.
Publicado: (2006)

Platelet Dysfunction in Thrombosis Patients Treated with Vitamin K Antagonists and Recurrent Bleeding
por: van der Meijden, Paola E. J., et al.
Publicado: (2013)

Therapeutic hypothermia in patients with coagulopathy following severe traumatic brain injury
por: Hifumi, Toru, et al.
Publicado: (2017)

Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding
por: Conen, Anna, et al.
Publicado: (2007)

Single-center experience with pediatric patients on ECMO who received recombinant factor VIIa for refractory bleeding
por: Alsohime, Fahad, et al.
Publicado: (2017)

Importance of fibrinogen in dilutional coagulopathy after neurosurgical procedures: A descriptive study
por: Nair, Shalini, et al.
Publicado: (2016)

Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review
por: Repessé, Xavier, et al.
Publicado: (2013)

In a trauma experimental pig model prothrombin complex concentrates and a specific antidote (idarucizumab) are effective to reverse the anticoagulant effects of dabigatran
por: Grottke, O, et al.
Publicado: (2014)

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
por: Zollner, S, et al.
Publicado: (2014)

Correction of hypothermic and dilutional coagulopathy with concentrates of fibrinogen and factor XIII: an in vitro study with ROTEM
por: Winstedt, Dag, et al.
Publicado: (2014)

Preclinical trauma studies of recombinant factor VIIa
por: Schreiber, Martin A, et al.
Publicado: (2005)

Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopenia
por: Tang, Yaqiong, et al.
Publicado: (2015)

Evaluation of the analytical performance of the PC100 platelet counter
por: Nagy, Magdolna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hi6or27rhcqnnkqe15tgvlte1d